Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s):  MEDXF

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. The Company is focused on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology. The Company has two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada division is a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. The division’s prescription products include Metoject (Methotrexate Injection), Rupall (Rupatadine), Cuvposa (Glycopyrrolate Oral Solution), Pediapharm Naproxen Suspension (Naproxen) and others. Medexus Pharma USA division is a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States. The division’s products include Rasuvo, IXINITY and Gleolan.


TSX:MDP - Post by User

Comment by Rockafellowon Mar 25, 2021 12:41pm
140 Views
Post# 32875913

RE:RE:The drug Gleolan ...

RE:RE:The drug Gleolan ...UR calculations r overdone I think...
They only got approval in Canada for Gleolan last month so 
Halifax was probably the first use of the product...
... Their sales on other drugs for last yr was about 110  $mil or 5$/sh....
... ...
The proposed sales this yr for a new drug treosultan is expected to be about $100 mil US so add another $5 bucks on the share price....
.... ...
This doesn't get approval until  August in USa but Canada may approve it in June so add Canada's part say $20 mil adds another buck/sh... Now were at $11/sh....
... ...
They r expecting sales of $200 mil plus this yr alone... An easy $10/sh...plus...
I can wait for news about Nasdaq and c the action... 

<< Previous
Bullboard Posts
Next >>